|
.gif) |
Vancomycin-intermediate Staphylococcus aureus (VISA), and Vancomycin-resistant
Staphylococcus aureus (VRSA)
2007 Case Definition
Clinical Description
S. aureus can produce a variety of syndromes with clinical manifestations including
skin and soft tissue infections, empyema, bloodstream infection, pneumonia, osteomyelitis, septic
arthritis, endocarditis, sepsis, and meningitis. S. aureus may also colonize individuals who remain
asymptomatic. The most frequent site of S. aureus colonization is the nares.
Laboratory Criteria
- Isolation of S. aureus from any body site.
AND
- Intermediate or resistance of the S. aureus isolate to vancomycin, detected and defined
according to Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) approved standards and
recommendations (Minimum Inhibitory Concentration [MIC]=4-8 µg/ml for VISA and MIC≥16 µg/ml for VRSA).
Case Classification
Confirmed: A case of vancomycin-intermediate or vancomycin-resistant S. aureus that is
laboratory-confirmed (MIC=4-8 µg/ml for VISA and MIC≥16 µg/ml for VRSA).
Reference
Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for Antimicrobial
Susceptibility Testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI, 2006.
See also:
Printable
Version
|
|
